South San Francisco, CA — August 19th, 2024 —
On February 28, 2025, Genentech will discontinue all marketing and commercial distribution of Fuzeon® (enfuvirtide) in the United States.
The decision to discontinue Fuzeon was made after a thorough assessment by Genentech. It is based on several considerations, including evolving clinical practice and significantly reduced medical need due to the novel alternative treatment options targeting the same indication. This action is not related to any quality, safety, or efficacy issues regarding the product. The U.S. Food and Drug Administration (FDA) has been notified.
Ensuring the well-being of patients is Genentech’s top priority, and we are committed to supporting patients and healthcare providers during this transition. Alternative treatment options for HIV are commercially available; we encourage patients to discuss treatment options with their doctor. Any questions from those impacted by this transition can call the Fuzeon support line at 1-877-4 FUZEON (1-877-438-9366).
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.